Preparation of PEG-rnodified nanostructured lipid carriers loaded with hydroxycamptothecin and tissue distribution in mice

Yaoxue Xuebao

Volumn 43, Issue 1, 2008, Pages 91-96

  Zhang, Xin Xin ^a,b   Gan, Yong ^b   Yang, Xing Gang ^a   Zhu, Chun Liu ^b   Gan, Li ^b   Nie, Shu Fang ^a   Pan, Wei San ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Hydroxycamptothecin; Lung targeting; Nanostructured lipid carrier; Tissue distribution

Indexed keywords

10 HYDROXYCAMPTOTHECIN; 10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; LIPID; MACROGOL DERIVATIVE; NANOPARTICLE;

ANIMAL; ARTICLE; BIOAVAILABILITY; BLOOD; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG STABILITY; FEMALE; LUNG; METABOLISM; MONONUCLEAR PHAGOCYTE; MOUSE; PARTICLE SIZE; PHAGOCYTOSIS; PHYSIOLOGY; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CAMPTOTHECIN; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; LIPIDS; LUNG; MICE; MONONUCLEAR PHAGOCYTE SYSTEM; NANOPARTICLES; PARTICLE SIZE; PHAGOCYTOSIS; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION;

EID: 38849095353     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Gong MT, Zhang JS, Dai XM. Pharmacokinetics of hydroxycamptothecin micro-emulsions in rats [J]. J China Pharm Univ, 2004,35: 324 -327.
2. Dong J, Guo JX, Ping QN. Preparation and stability of hydroxycamptothecin lipid emulsion [J]. Chin New Drugs J, 2005,14:720-723.
3. Ryotaro K, Hiraku O, Yoshiharu M. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin [J]. Eur J Pharm Biopharm, 2007,67;9-17.
4. Zhang ZR, Lu W. Study on liver targeting and sustained release hydroxycamptothecin polybutylcyanoacrylate nanoparticles [J]. Acta Pharm Sin, 1997,32: 222-227.
5. Souto EB, Wissing SA, Barbosa CM, et al. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery [J]. Int J Pharm, 2004, 278:71-77.
6. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs [J]. Int J Pharm, 2002,242:121-128.
7. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations [J]. Adv Drug Deliv Rev, 2002,54(Suppl):131-155.
8. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 [J]. Cancer Res, 1991,51:4187-4191.
9. Sadzuka Y, Nakade A, Hirama R, et al. Effect of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome [J]. Int J Pharm, 2002,238:171-180.
10. Shi B, Fang C, You MX, et al. Stealth PEG-PHDCA niosomes: effects of chain length of PEG on niosomes in vitro complement consumption and phagocytic uptake [J]. Acta Pharm Sin. 2005,40:976-981.
11. Riley T, Govender T, Stolnik S, et al. Colloidal stability and drug incorporation aspects of micellar-like PLA-PEC nanoparticles [J]. Colloids Surf B Bioiaterfaces, 1999; 147-159.
12. Serranl AG, Perez GJ. Protein-lipid interactions and surface activity in the pulmonary surfactant system [J]. Chem Phys Lipids, 2006,141:105-118.